✦ LIBER ✦

Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

✍ Scribed by Dr. Gopal Krishna; Dr. Malaz AbuTarif; Dr. Fengjuan Xuan; Ms. Monika Martinho; Dr. David Angulo; Dr. Oliver A. Cornely

Book ID: 115049632
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 193 KB
Volume: 28
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.28.10.1223

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factors influencing the pharmacokinetics

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

✍ Vehreschild, J. J.; Müller, C.; Farowski, F.; Vehreschild, M. J. G. T.; Cornely, 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 367 KB

A multicenter, randomized trial of posac

A multicenter, randomized trial of posaconazole (POS) vs fluconazole (FLU) or itraconazole (ITZ) for prophylaxis of invasive fungal infections (IFIs) in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) receiving intensive chemotherapy

✍ D.J. Winston; O.A. Cornely; J. Maertens; J. Perfect; D. Helfgott; A.J. Ullmann; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Pharmacokinetics of amsacrine in patient

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia

✍ J. L. Jurlina; A. R. Varcoe; J. W. Paxton 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 503 KB

Tolerability, Pharmacodynamics, and Phar

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

✍ Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 188 KB

Prognostic relevance of achieving cytoge

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

✍ Sebastian Balleisen; Andrea Kuendgen; Barbara Hildebrandt; Rainer Haas; Ulrich G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy. Assessment of remission and treatment decisions are based on cytological findings. We analyzed the prognostic impact of cytogenetic remission st

Predictors and outcome of acute kidney i

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Amit Lahoti; Hagop Kantarjian; Abdulla K. Salahudeen; Farhad Ravandi; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views